DC
RGLS

Deere & Company’s Regulus Therapeutics RGLS Stock Holding History

Deere & Company’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-240
Closed -$462K – 1043
2014
Q4 		$462K Buy
+240
New +$427K 0.03% 656

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deere & Company's RGLS Position: Q1 2015 in Review

Deere & Company sold out of Regulus Therapeutics (RGLS) in Q1 2015, closing a stake of 240 shares — an estimated $462K sold.

Deere & Company first reported a position in RGLS in Q4 2014 and held it in 1 quarter. The position peaked at $462K in Q4 2014. 88 funds tracked by Wall St. Rank hold RGLS as of Q1 2015.

  • Deere & Company reported no remaining Regulus Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Deere & Company sold 240 Regulus Therapeutics shares in Q1 2015, an estimated $462K.
  • Deere & Company first reported a position in Regulus Therapeutics in Q4 2014 and held it in 1 quarter.
  • Deere & Company's Regulus Therapeutics position peaked at $462K in Q4 2014.
  • 88 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q1 2015.

Based on Deere & Company's 13F filing for Q1 2015, filed 13 May 2015.